HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Patient-controlled epidural analgesia or multimodal pain regimen with periarticular injection after total hip arthroplasty: a randomized, double-blind, placebo-controlled study.

AbstractBACKGROUND:
The optimal postoperative analgesia after primary total hip arthroplasty remains in question. This randomized, double-blind, placebo-controlled study compared the use of patient-controlled epidural analgesia (PCEA) with use of a multimodal pain regimen including periarticular injection (PAI). We hypothesized that PAI would lead to earlier readiness for discharge, decreased opioid consumption, and lower pain scores.
METHODS:
Forty-one patients received PAI, and forty-three patients received PCEA. Preoperatively, both groups were administered dexamethasone (6 mg, orally). The PAI group received a clonidine patch and sustained-release oxycodone (10 mg), while the PCEA group had placebo. Both groups received combined spinal-epidural anesthesia and used an epidural pain pump postoperatively; the PAI group had normal saline solution, while the PCEA group had bupivacaine and hydromorphone. The primary outcome, readiness for discharge, required the discontinuation of the epidural, a pain score of <4 (numeric rating scale) without parenteral narcotics, normal eating, minimal nausea, urination without a catheter, a dry surgical wound, no acute medical problems, and the ability to independently transfer and walk 12.2 m (40 ft).
RESULTS:
The mean time to readiness for discharge (and standard deviation) was 2.4 ± 0.7 days (PAI) compared with 2.3 ± 0.8 days (PCEA) (p = 0.86). The mean length of stay was 3.0 ± 0.8 days (PAI) compared with 3.1 ± 0.7 days (PCEA) (p = 0.46). A significant mean difference in pain score of 0.74 with ambulation (p = 0.01; 95% confidence interval [CI], 0.18 to 1.31) and 0.80 during physical therapy (p = 0.03; 95% CI, 0.09 to 1.51) favored the PCEA group. The mean opioid consumption (oral morphine equivalents in milligrams) was significantly higher in the PAI group on postoperative day 0 (43 ± 21 compared with 28 ± 23; p = 0.002) and postoperative days 0 through 2 (136 ± 59 compared with 90 ± 79; p = 0.004). Opioid-Related Symptom Distress Scale (ORSDS) composite scores for severity and bothersomeness as well as scores for nausea, vomiting, and itchiness were significantly higher in the PCEA group (p < 0.05). Quality of Recovery-40 scores and patient satisfaction were similar.
CONCLUSIONS:
PAI did not decrease the time to discharge and was associated with higher pain scores and greater opioid consumption but lower ORSDS scores compared with PCEA. The choice for analgesic regimen may depend on a particular patient's threshold for pain and the potential side effects.
AuthorsKethy M Jules-Elysee, Amanda K Goon, Geoffrey H Westrich, Douglas E Padgett, David J Mayman, Amar S Ranawat, Chitranjan S Ranawat, Yi Lin, Richard L Kahn, Devan D Bhagat, Enrique A Goytizolo, Yan Ma, Shane C Reid, Jodie Curren, Jacques T YaDeau
JournalThe Journal of bone and joint surgery. American volume (J Bone Joint Surg Am) Vol. 97 Issue 10 Pg. 789-98 (May 20 2015) ISSN: 1535-1386 [Electronic] United States
PMID25995489 (Publication Type: Journal Article, Randomized Controlled Trial)
CopyrightCopyright © 2015 by The Journal of Bone and Joint Surgery, Incorporated.
Chemical References
  • Analgesics
  • Oxycodone
  • Clonidine
Topics
  • Administration, Cutaneous
  • Aged
  • Aged, 80 and over
  • Analgesia, Epidural (methods)
  • Analgesia, Patient-Controlled (methods)
  • Analgesics (administration & dosage)
  • Arthroplasty, Replacement, Hip
  • Clonidine (administration & dosage)
  • Double-Blind Method
  • Drug Therapy, Combination
  • Female
  • Humans
  • Injections, Intra-Articular
  • Length of Stay
  • Male
  • Middle Aged
  • Oxycodone (administration & dosage)
  • Pain Measurement
  • Pain, Postoperative (prevention & control)
  • Patient Satisfaction
  • Postoperative Care (methods)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: